Intravenous abciximab as a rescue therapy for immediate reocclusion after successful mechanical thrombectomy in acute ischemic stroke patients.

Abciximab / pharmacology Acute Disease Administration, Intravenous / methods Aged Female Humans Ischemic Stroke / drug therapy Male Middle Aged Platelet Aggregation Inhibitors / pharmacology Thrombectomy / methods
Abciximab Antiplatelet Therapy Large Vessel Occlusion Mechanical Thrombectomy Reocclusion

Journal

Platelets
ISSN: 1369-1635
Titre abrégé: Platelets
Pays: England
ID NLM: 9208117

Informations de publication

Date de publication:
17 Feb 2022
Historique:
pubmed: 13 4 2021
medline: 30 3 2022
entrez: 12 4 2021
Statut: ppublish

Résumé

Immediate reocclusion after mechanical thrombectomy (MT) for acute ischemic stroke (AIS) is a rare but devastating condition associated with poor functional outcome. The aim of this study was to gain insights into the mechanisms underlying immediate reocclusion, and to evaluate the efficacy and safety of the glycoprotein IIb/IIIa antagonist abciximab, for its treatment. Clinical data were collected from April 2015 to April 2019 in a monocentric prospective registry of AIS patients treated by MT. All patients with immediate reocclusion were retrospectively selected and subdivided into 2 groups according to abciximab treatment status.

Identifiants

DOI: 10.1080/09537104.2021.1894326 PMID: 33840346
pubmed: 33840346
doi: 10.1080/09537104.2021.1894326
doi:

Substances chimiques

Platelet Aggregation Inhibitors 0
Abciximab X85G7936GV

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

285-290

Auteurs

François Delvoye (F)

Rothschild Foundation Hospital, Interventional Neuroradiology Department, Paris, France.
University of Liege, Belgium.
ORCID: 0000-0002-0697-2156

Stephane Loyau (S)

Laboratory of Vascular Translational Science, U1148 INSERM, Université De Paris, Paris, France.

Julien Labreuche (J)

Lille, France.

Guillaume Taylor (G)

Rothschild Foundation Hospital, Intensive Care Department, Paris, France.

Benjamin Maier (B)

Rothschild Foundation Hospital, Interventional Neuroradiology Department, Paris, France.
Laboratory of Vascular Translational Science, U1148 INSERM, Université De Paris, Paris, France.

Michel Piotin (M)

Rothschild Foundation Hospital, Interventional Neuroradiology Department, Paris, France.
Laboratory of Vascular Translational Science, U1148 INSERM, Université De Paris, Paris, France.

Raphael Blanc (R)

Rothschild Foundation Hospital, Interventional Neuroradiology Department, Paris, France.
Laboratory of Vascular Translational Science, U1148 INSERM, Université De Paris, Paris, France.

Simon Escalard (S)

Rothschild Foundation Hospital, Interventional Neuroradiology Department, Paris, France.

Lucas Di Meglio (L)

Laboratory of Vascular Translational Science, U1148 INSERM, Université De Paris, Paris, France.

Malek Ben Maacha (M)

Clinical Research Unit, Rothschild Foundation Hospital, Paris, France.

Hocine Redjem (H)

Rothschild Foundation Hospital, Interventional Neuroradiology Department, Paris, France.

Stanislas Smajda (S)

Rothschild Foundation Hospital, Interventional Neuroradiology Department, Paris, France.

Gabriele Ciccio (G)

Rothschild Foundation Hospital, Interventional Neuroradiology Department, Paris, France.

Solène Hébert (S)

Rothschild Foundation Hospital, Interventional Neuroradiology Department, Paris, France.

Candice Sabben (C)

Rothschild Foundation Hospital, Neurology Department, Paris, France.

Martine Jandrot-Perrus (M)

Laboratory of Vascular Translational Science, U1148 INSERM, Université De Paris, Paris, France.

Alain Maertens De Noordhout (A)

University of Liege, Belgium.

Mikael Mazighi (M)

Rothschild Foundation Hospital, Interventional Neuroradiology Department, Paris, France.
Laboratory of Vascular Translational Science, U1148 INSERM, Université De Paris, Paris, France.
Université De Paris, France.
DHU Neurovasc.

Benoit Ho-Tin-Noé (B)

Laboratory of Vascular Translational Science, U1148 INSERM, Université De Paris, Paris, France.

Jean-Philippe Desilles (JP)

Rothschild Foundation Hospital, Interventional Neuroradiology Department, Paris, France.
Laboratory of Vascular Translational Science, U1148 INSERM, Université De Paris, Paris, France.
Université De Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Fragments d'immunoglobuline › Fragments Fab d'immunoglobuline › Abciximab › Intravenous abciximab as a rescue therapy for...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie aigüe › Intravenous abciximab as a rescue therapy for...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Voies d'administration de substances chimiques et des médicaments › Administration par voie intraveineuse › Intravenous abciximab as a rescue therapy for...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Intravenous abciximab as a rescue therapy for...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Intravenous abciximab as a rescue therapy for...
questionsmedicales.fr › Maladies cardiovasculaires › Maladies vasculaires › Angiopathies intracrâniennes › Accident vasculaire cérébral › Accident vasculaire cérébral ischémique › Intravenous abciximab as a rescue therapy for...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Intravenous abciximab as a rescue therapy for...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents hématologiques › Antiagrégants plaquettaires › Intravenous abciximab as a rescue therapy for...
questionsmedicales.fr › Procédures de chirurgie opératoire › Procédures de chirurgie cardiovasculaire › Procédures de chirurgie vasculaire › Thrombectomie › Intravenous abciximab as a rescue therapy for...